Therapy News and Research

RSS

Epilepsy may arise from complex mixture of altered ion channels

Imagine two flat screen televisions tuned to the same channel and sitting side-by-side. From a distance, their pictures are virtually the same, however up close, you can see subtle variations in the pixels - one blurred here, another dropped out there.

24 Jun 2011

BIOTRONIK to introduce Lumax DX system for complete atrial arrhythmia diagnosis

BIOTRONIK SE & Co. KG, a worldwide leader in manufacturing cardiac medical devices, announced today that the innovative new Lumax 540 VR-T DX single-chamber implantable cardiac defibrillator (ICD) and Linoxsmart S DX cardiac lead system will be launched this coming week at the EHRA EUROPACE electrophysiology congress in Madrid, Spain.

24 Jun 2011

Scientists uncover new therapeutic target for Huntington's disease

UT Southwestern Medical Center researchers have identified compounds that appear to inhibit a signaling pathway in Huntington's disease, a finding that may eventually lead to a potential drug therapy to help slow the progression of degenerative nerve disorders.

24 Jun 2011

Growth-braking tumor-suppressor gene slows growth of childhood brain tumors

Johns Hopkins researchers have found a likely explanation for the slow growth of the most common childhood brain tumor, pilocytic astrocytoma. Using tests on a new cell-based model of the tumor, they concluded that the initial process of tumor formation switches on a growth-braking tumor-suppressor gene, in a process similar to that seen in skin moles.

24 Jun 2011

GTRI develops novel iPhone application for patients with Parkinson's

Researchers at the Georgia Tech Research Institute (GTRI) have developed a novel iPhone application that may enable persons with Parkinson's disease and certain other neurological conditions to use the ubiquitous devices to collect data on hand and arm tremors and relay the results to medical personnel.

24 Jun 2011

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Endo Pharmaceuticals announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan. 7, 2011 Action Letter relating to Endo's new drug application (NDA) for a new formulation of OPANA ER has been accepted.

24 Jun 2011

Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's

Lithium profoundly prevents the aggregation of toxic proteins and cell loss associated with Parkinson's disease (PD) in a mouse model of the condition.

24 Jun 2011

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

24 Jun 2011

AMT receives CHMP opinion on Glybera Marketing Authorisation Application

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.

24 Jun 2011

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

24 Jun 2011

GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a third site for testing the therapeutic potential of its HIV/AIDS vaccine.

24 Jun 2011

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.

24 Jun 2011

ACS designates Stanford as level-2 pediatric trauma center

Stanford's trauma center has been verified as a level-2 pediatric trauma center by the American College of Surgeons.

24 Jun 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.

24 Jun 2011

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today that their lead program, SBC-102, an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, currently in clinical trials, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).

23 Jun 2011

Spinal manipulative therapy provides minor but significant benefits for patients with chronic low back pain

Spinal manipulative therapy (SMT) has significant but very small benefits for patients with chronic low back pain, according to a special review article in the June 1 issue of Spine.

23 Jun 2011

Proton beam radiotherapy appears to control breast cancer with minimal side-effects

A treatment that has virtually no side effects has been found to be an effective weapon for fighting early-stage breast cancer, according to results of a clinical trial conducted at Loma Linda University Medical Center.

23 Jun 2011

Insights into type I diabetes

A new signal pathway that renders the insulin-releasing beta cell more sensitive to high levels of blood glucose has been discovered by researchers at the Swedish medical university Karolinska Institutet. A second new study reveals a possible way to delay the disease by inhibiting a lipoprotein.

23 Jun 2011

MEDA seeks marketing authorization for Zyclara in Europe

“Zyclara will strengthen Meda's dermatology franchise in Europe. We look forward to provide AK patients with a new product that can treat larger areas of the skin”

23 Jun 2011

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd and to initiate closure of the study.

23 Jun 2011

Therapy News and Research

Epilepsy may arise from complex mixture of altered ion channels

BIOTRONIK to introduce Lumax DX system for complete atrial arrhythmia diagnosis

Scientists uncover new therapeutic target for Huntington's disease

Growth-braking tumor-suppressor gene slows growth of childhood brain tumors

GTRI develops novel iPhone application for patients with Parkinson's

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

AMT receives CHMP opinion on Glybera Marketing Authorisation Application

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

ACS designates Stanford as level-2 pediatric trauma center

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

Spinal manipulative therapy provides minor but significant benefits for patients with chronic low back pain

Proton beam radiotherapy appears to control breast cancer with minimal side-effects

Insights into type I diabetes

MEDA seeks marketing authorization for Zyclara in Europe

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News